Business Context and Reporting Period
The provided filing is Gemphire Therapeutics Inc.’s Form 10-K for the fiscal year ended December 31, 2017, filed March 20, 2018. The request metadata identifies “Metavia Inc.,” but the filing itself identifies the registrant as Gemphire Therapeutics Inc.; this discrepancy should be verified.
Gemphire is a clinical-stage biopharmaceutical company developing gemcabene, a once-daily oral therapy targeting dyslipidemia and NAFLD/NASH. The company had no approved products or commercial revenue and depended on the clinical, regulatory and financing success of gemcabene.
Key Financial Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| General and administrative expense | $10.4 million | $6.0 million | +$4.5 million |
| Research and development expense | $22.7 million | $8.7 million | +$13.9 million |
| Total operating expenses | $33.1 million | $14.7 million | +$18.4 million |
| Net loss | $33.4 million | $14.6 million | Loss increased by $18.8 million |
| Basic and diluted loss per share | $3.23 loss | $2.57 loss | Loss per share increased |
| Cash used in operating activities | $26.9 million | $11.0 million | Use increased by $15.9 million |
| Cash and cash equivalents | $18.5 million | $24.0 million | Decreased by $5.6 million |
| Total assets | $19.0 million | $24.8 million | Decreased by $5.7 million |
| Total liabilities | $15.1 million | $4.1 million | Increased by $11.0 million |
| Stockholders’ equity | $3.9 million | $20.6 million | Decreased by $16.7 million |
Gross margin and operating margin are not meaningful because the company generated no revenue. The 2017 operating loss was approximately equal to total operating expenses. Share-based compensation was $5.3 million, including $4.1 million in general and administrative expense and $1.2 million in research and development expense.
Fourth-quarter 2017 net loss was $6.7 million, compared with $7.2 million in the fourth quarter of 2016. Fourth-quarter research and development expense was $5.1 million and general and administrative expense was $1.5 million.
Material Changes Versus the Prior Comparable Period
- Research and development spending increased approximately 159%, primarily due to clinical trial development, regulatory consulting, preclinical studies and manufacturing activities.
- General and administrative expense increased approximately 75%, reflecting increased staffing, public-company costs and $2.6 million of separation-related compensation and accelerated stock-option vesting costs for the former chief executive officer.
- Cash used in operations increased to $26.9 million from $11.0 million, reflecting the company’s expanded clinical development program and higher operating losses.
- The company raised approximately $11.3 million in net proceeds from a March 2017 private placement and borrowed $10.0 million under a Silicon Valley Bank term loan.
- At December 31, 2017, 10.6 million common shares were outstanding, compared with 9.3 million at December 31, 2016. The private placement also included warrants to purchase 993,204 shares, of which 978,204 remained outstanding at year-end.
- The company completed a subsequent public offering in the first quarter of 2018, issuing 3,592,858 shares at $7.00 per share and receiving approximately $23.0 million in net proceeds.
Guidance, Outlook, Risks and Unusual Items
- Management stated that cash at December 31, 2017, together with the first-quarter 2018 public offering proceeds, was expected to fund operations into at least mid-2019 and through the planned INDIGO-1 study, initiation of a dyslipidemia Phase 3 program and completion of two NASH/NAFLD Phase 2a studies. Management also stated that additional capital would be required.
- Top-line results from the 90-patient INDIGO-1 severe hypertriglyceridemia trial were expected in the second quarter of 2018.
- Top-line results from the familial partial lipodystrophy Phase 2a trial were expected in the second half of 2018, and pediatric NAFLD/NASH results were expected in early 2019.
- The company planned an End-of-Phase-2 meeting with the FDA to discuss Phase 3 registration trials and long-term safety requirements. The timing depended partly on FDA review of two-year rodent carcinogenicity studies.
- Gemcabene remained subject to a partial clinical hold restricting trials longer than six months until required rodent carcinogenicity studies were completed and reviewed. Failure to lift the hold could delay long-term safety studies and regulatory approval.
- The company believed a cardiovascular outcomes trial was unlikely to be required before approval, but acknowledged that the FDA could impose such a requirement, significantly increasing costs and delaying development.
- The company had a $10.0 million term loan outstanding at year-end. The loan matured February 1, 2021, carried interest at a floating rate based on the prime rate, included a 10% final payment fee, and was secured by substantially all assets other than intellectual property.
- An additional $5.0 million loan tranche was conditionally available through July 31, 2018. If the FDA did not lift the partial clinical hold by that date, the company could be required to fully prepay the loan or maintain restricted cash equal to amounts owed.
- The Pfizer license agreement required potential milestone payments of up to $37 million and tiered royalties ranging from the high single digits to low teens on future net sales. Pfizer could revoke the license if the company was unable to adequately commercialize gemcabene by April 2021.
- The company reported no material pending legal proceedings. Ernst & Young issued an unqualified audit opinion on the financial statements; the audit did not include an attestation opinion on internal control over financial reporting because of the company’s emerging growth company status.
Most Important Facts for Investors to Verify
- Confirm the registrant identity: the source filing is for Gemphire Therapeutics Inc., not Metavia Inc.
- Verify the status and results of INDIGO-1, the NASH/NAFLD trials, and the FDA’s review of the carcinogenicity studies and partial clinical hold.
- Assess cash runway after the $23.0 million 2018 offering, ongoing operating cash burn and the timing and terms of any required additional financing.
- Review the SVB loan covenants, conditional $5.0 million tranche, repayment triggers, final payment fee and potential acceleration or restricted-cash requirements.
- Evaluate whether early-stage clinical results can be replicated in adequately powered Phase 3 trials and whether the FDA will require a cardiovascular outcomes trial or additional long-term safety studies.
- Review dilution from outstanding warrants, stock options and subsequent equity offerings.
- Assess the scope, remaining term and enforceability of the Pfizer license and the company’s patent portfolio.
- Verify management’s assumption that gemcabene’s existing cash and financing will fund operations through mid-2019, given the company’s lack of revenue and continuing losses.